The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis
Open accessAbstract
Introduction: Cerebrospinal fluid analysis and other measurements of amyloidosis, such as amyloid‐binding positron emission tomography studies, are limited by cost and availability. There is a need for a more practical amyloid β (Aβ) biomarker for central nervous system amyloid deposition. Methods: We adapted our previously reported stable isotope labeling kinetics protocol to analyze the turnover kinetics and concentrations of Aβ38, Aβ40, and Aβ42 in human plasma. Results: Aβ isoforms have a half‐life of approximately 3 hours in plasma. Aβ38 demonstrated faster turnover kinetics compared with Aβ40 and Aβ42. Faster fractional turnover of Aβ42 relative to Aβ40 and lower Aβ42 and Aβ42/Aβ40 concentrations in amyloid‐positive participants were observed. Discussion: Blood plasma Aβ42 shows similar amyloid‐associated alterations as we have previously reported in cerebrospinal fluid, suggesting a blood‐brain transportation mechanism of Aβ. The stability and sensitivity of plasma Aβ measurements suggest this may be a useful screening test for central nervous system amyloidosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“an 8-year follow-up study of 599 volunteers (average age 70 years) in Australia found that cognitively normal PET amyloid-positive people had an elevated risk of developing Alzheimer's disease compared with amyloid negative (17·7% vs 8·1%; OR 2·4, 95% CI 1·5–4·0).184”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Plasma Aβ measures now show promise [202,203].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [202]
The cited source says what the claim attributes to it.
In the citing paper
“While imaging/CSF biomarker data on subsets of individuals from well-designed community-based cohorts would provide additional research value, incorporating biomarkers on a large scale in many settings will require low-cost and minimally invasive biomarkers (e.g., blood or saliva) that are now emerging [202–205].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [202]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Over 80% of the 266 people who were PET amyloid-positive did not go onto develop a cognitive impairment within 8 years, showing positive status does not predict impairment for most people in a timeframe that might be a useful prognostic window.”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Follow-up at 5 years of amyloid-positive participants with normal cognition or mild cognitive impairment versus amyloid negative people found the same pattern of increased risk (2·6, 1·4–4·9).”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measured
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Risk also increases per 1 year of age (HR 1·05, 95% CI 0·55–2·0/year), and APOEε4 status (2·6, 1·4–5·0).184”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [184]
Experimental — accuracy not yet measuredIn the citing paper
“Blood biomarkers for the presymptomatic phase of Alzheimer’s disease are largely lacking, although recent progress in the analysis of amyloid-β, tau, and neurofilament light chain (NfL) in the blood have been reported5–10.”
From Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) · cites this paper as [8]
In the citing paper
“Recent studies demonstrate the ability to detect CNS Aβ deposition via the use of plasma assessment of Aβ species”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Ovod et al., 2017
In the citing paper
“Most recently, 2 independent groups demonstrated improved accuracy for plasma Aβ42/Aβ40 using immunoprecipitation–mass spectrometry assays.19,20”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [20]
In the citing paper
“In mass spectrometry–based techniques, 2 recent studies have provided overall better accuracies for plasma Aβ42/Aβ40 (AUC, 0.84-0.97 depending on population and reference standard).19,20”
From Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status (2019) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain
Deane, R., Du Yan, S., Submamaryan, R. K., LaRue, B., Jovanovic, S., Hogg, E., Welch, D., Manness, L., Lin, C., Yu, J., et al. (2003) · Nature Medicine · doi:10.1038/nm890 · Cited by 1,426
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291
Beach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 1×
“3%, respectively, when confirmed by postmortem histopathology [4].”
BackgroundLRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms
Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., Xu, F., Parisi, M., LaRue, B., Hu, H. W., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.017 · Cited by 828
Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Self-citationGalasko, D., Chang, L., Motter, R., Clark, C. M., Kaye, J., Knopman, D., Thomas, R., Kholodenko, D., Schenk, D., Lieberburg, I., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.937 · Cited by 442
Plasma Aβ40 and Aβ42 and Alzheimer’s disease: Relation to age, mortality, and risk
Mayeux, R., Honig, L. S., Tang, M.-X., Manly, J., Stern, Y., Schupf, N., & Mehta, P. D. (2003) · Neurology · doi:10.1212/01.wnl.0000091890.32140.8f · Cited by 434
Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357
Self-citationAge but Not Diagnosis Is the Main Predictor of Plasma Amyloid β-Protein Levels
Fukumoto, H., Tennis, M. K., Locascio, J. J., Hyman, B. T., Growdon, J. H., & Irizarry, M. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.958 · Cited by 258
Cited by
Sorted by citations
Items 401–500 of 586
Li, L., Zhen, Y., Decker, R. L., Willis, B. A., Waters, D. G., Liu, P., Hake, A. M., Demattos, R. B., & Ayan‐Oshodi, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180925 · Cited by 6
Zetterberg, H., Apostolova, L. G., & Snyder, P. J. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.10.001 · Cited by 6
Development of Alzheimer’s disease in Down syndrome
García, O. A., Domínguez-de-la-Cruz, E., Luna-Martínez, I. G., Garnett-Carbajal, J. A., & Villegas-Piña, J. A. (2025) · Exploration of neuroscience · doi:10.37349/en.2025.1006104 · Cited by 4
Joo, S. H., & Lee, C. U. (2021) · Psychiatry Investigation · doi:10.30773/pi.2021.0104 · Cited by 5
Giudici, K. V., Guyonnet, S., Morley, J. E., Nguyen, A. D., Aggarwal, G., Parini, A., Li, Y., Bateman, R. J., Vellas, B. J., Barreto, P. D. S., et al. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac015 · Cited by 6
Self-citationLu, W., Giudici, K. V., Morley, J. E., Guyonnet, S., Parini, A., Aggarwal, G., Nguyen, A. D., Li, Y., Bateman, R. J., Vellas, B. J., et al. (2022) · GeroScience · doi:10.1007/s11357-022-00554-y · Cited by 5
Self-citationPetersen, R. C., Graf, A., Brady, C., Santi, S. D., Florian, H., Landen, J. W., Pontecorvo, M., RANDOLPH, C. C., Sink, K. M., Carrillo, M. C., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12434 · Cited by 4
Shim, Y. (2023) · Current Alzheimer Research · doi:10.2174/0115672050284054240119101834 · Cited by 5
Neue Biomarker für die Alzheimer-Krankheit in Liquor und Blut
Vogelgsang, J. S., & Wiltfang, J. (2019) · Der Nervenarzt · doi:10.1007/s00115-019-0772-9 · Cited by 5
Wiltfang, J., Esselmann, H., & Barnikol, U. B. (2021) · Psychiatrische Praxis · doi:10.1055/a-1369-3133 · Cited by 5
Alishahi, F., Beam, C. R., Gatz, M., Schneider, L. S. S., Nation, D. A., Yassine, H. N., Kaplan, H. S., Ganesan, S., Pappas, I., Davis, D. W., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251340999 · Cited by 4
Bacci, J. R., Ryan, J. L., Murray, A. M., Wu, Z., Woods, R. L., Berk, M., & Mielke, M. M. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.71007 · Cited by 4
Advances in plasma biomarkers for the diagnosis of Alzheimer’s disease
Wu, H., Liu, L., & Zeng, L. (2026) · Brain Research · doi:10.1016/j.brainres.2025.150138 · Cited by 4
Advances in ultrasensitive detection technologies for blood-based biomarkers of Alzheimer's disease
Mou, Y., Sun, C., Deng, K., Lin, F., Yang, Z., Wang, Y., Deng, X., Yang, F., Hu, X., & Jiang, Q. (2026) · Journal of Materials Chemistry B · doi:10.1039/d5tb02633d · Cited by 4
Management of MCI in the Outpatient Setting
Abramowitz, A., & Weber, M. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01514-3 · Cited by 3
Malaty, G. R., Decourt, B., Shill, H. A., & Sabbagh, M. N. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-240110 · Cited by 4
Moradi, E., Dahnke, R., Imani, V., Christian Gaser, B., Solomon, A., Tohka, J., & Initiative, T. A. D. N. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.06.010 · Cited by 4
Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers
Chen, T., Lin, K., Lin, S., Lee, Y., Lin, Y., Wang, C.-Y., Chen, J., & Wang, P. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.619388 · Cited by 4
Ficiarà, E., Stura, I., Guiot, C., & Venturino, E. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111194 · Cited by 5
Innovative SALDI mass spectrometry analysis for Alzheimer's disease synthetic peptides detection
Cournut, A., Moustiez, P., Coffinier, Y., Enjalbal, C., & Bich, C. (2023) · Talanta · doi:10.1016/j.talanta.2023.125357 · Cited by 3
Jemimah, S., Abuhantash, F., & Shehhi, A. A. (2025) · PLoS ONE · doi:10.1371/journal.pone.0320360 · Cited by 4
Jang, J., & Kim, S. (2019) · Journal of the Korean Neurological Association · doi:10.17340/jkna.2019.1.1 · Cited by 4
Sabherwal, S., Föcking, M., English, J. A., Fitzsimons, S., Hryniewiecka, M., Wynne, K. J., Scaife, C., Healy, C., Cannon, M. D., Belton, O., et al. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.05.002 · Cited by 5
Evolution of Detecting Early Onset of Alzheimer’s Disease: From Neuroimaging to Optical Immunoassays
Hsiao, W. W., Angela, S., Le, T., Ku, C., Hu, P., & Chiang, W. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221202 · Cited by 4
Delrieu, J. (2022) · Wiley eBooks · doi:10.1002/9781119484288.ch63 · Cited by 4
Bateman, R. J., Li, Y., McDade, E., Guerra, J. J. L., Clifford, D. B., Atri, A., Mills, S. L., Santacruz, A. M., Wang, G., Supnet, C. B., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4906344 · Cited by 4
Self-citationShin, H.-Y., Yim, T., Heo, H.-M., Jahng, G., Kwon, S., Cho, S., Park, S.-U., Jung, W., Moon, S., Ko, C., et al. (2022) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-022-03805-9 · Cited by 3
Vers un diagnostic biologique sanguin de la maladie d’Alzheimer ?
Delaby, C., & Lehmann, S. (2024) · médecine/sciences · doi:10.1051/medsci/2024037 · Cited by 3
Guo, Y., Liu, T., Chen, H., Huang, W., Zhang, K., & Chen, F. (2025) · European Radiology · doi:10.1007/s00330-025-11706-x · Cited by 3
Fernández‐Eulate, G., Alberro, A., Muñoz‐Culla, M., Zulaica, M., Zufiría, M., Barandiarán, M., Etxeberría, I., Yanguas, J. J., Gallardo, M. M., Soberón, N. E., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00380 · Cited by 4
Recent Advances in the Quest for Treatment and Management of Alzheimer and Other Dementia
Tanwir, S. E., & Kumar, A. (2019) · Open Journal of Medicinal Chemistry · doi:10.4236/ojmc.2019.91001 · Cited by 3
Tang, P.-U., Wu, I.-H., Lao, I.-H., Leong, W., & Hu, C. (2020) · Innovations in Digital Health Diagnostics and Biomarkers · doi:10.36401/iddb-20-04 · Cited by 3
Sex differences in CSF biomarkers of Alzheimer’s disease
Mielke, M. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819344-0.00012-0 · Cited by 4
Potential biomarkers of early diagnosis of Alzheimer’s disease
Bogolepova, A. N., Makhnovich, E. V., Коваленко, Е. А., & Osinovskaya, N. A. (2022) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20221220917 · Cited by 3
Annual stability of the plasma Aß40/42 ratio and associated factors
Nakamura, T., Kawarabayashi, T., Nakahata, N., Itoh, K., Ihara, K., Nakaji, S., Ikeda, Y., Takatama, M., & Shoji, M. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51770 · Cited by 5
Biomarkers for Alzheimer's Disease – An Overview
Tyagi, U., Tripathy, D. B., Gupta, A., Bisht, K., & Nain, A. (2024) · Macromolecular Symposia · doi:10.1002/masy.202200218 · Cited by 3
The relationship between anxiety and levels of Alzheimer's disease plasma biomarkers
Bernard, M. A., Boutajangout, A., Debure, L., Ahmed, W., Briggs, A., Boza-Calvo, C., Vedvyas, A., Marsh, K., Bubu, O. M., Osorio, R. S., et al. (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241295324 · Cited by 3
Han, J., Feng, G., Liu, H.-W., Yi, J., Wu, J., & Yao, X. (2022) · PubMed Central · Cited by 3
Screening with a high-precision blood-based assay for Alzheimer disease
Bendlin, B. B., & Zetterberg, H. (2019) · Neurology · doi:10.1212/wnl.0000000000008080 · Cited by 3
Advances in Alzheimer's Disease Biomarkers
Li, K., Gao, Y., Liu, M., & Chen, Y. (2024) · Current Alzheimer Research · doi:10.2174/0115672050366767241223050957 · Cited by 3
Sato, K., Niimi, Y., Ihara, R., Iwata, A., Suzuki, K., & Iwatsubo, T. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70065 · Cited by 2
Nashiro, K., Cahn, B. R., Choi, P., Lee, H. R. J., Satchi, S., Min, J., Yoo, H. J., Cho, C., Mercer, N., Sordo, L., et al. (2025) · Psychophysiology · doi:10.1111/psyp.70182 · Cited by 2
Duan, X., Wang, F., Liu, W., Xie, Y., Yang, M., Ping, Y., Pan, Y., Wei, Z., Li, H., Zhang, Q.-P., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13346-z · Cited by 4
Fandos, N., Pascual‐Lucas, M., Sarasa, L., Terencio, J. V., Sáez, M. E., Tartari, J. P., Sanabria, Á., Sotolongo‐Grau, Ó., Cano, A. C., Tárraga, L., et al. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100465 · Cited by 2
Vigneswaran, S., Verberk, I. M. W., Rousset, R. Z., Gouda, M., Trieu, C., Claessen, T., van de Giessen, E., Lemstra, A. W., Wilson, D. J., Pijnenburg, Y. A. L., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01979-9 · Cited by 3
Structural signature of plasma proteins classifies the status of Alzheimer’s disease
Son, A., Kim, H., Diedrich, J. K., Bamberger, C., Wilkins, H., Burns, J. M., Morris, J. K., Rissman, R. A., Swerdlow, R. H., & Yates, J. R. (2026) · Nature Aging · doi:10.1038/s43587-026-01078-2 · Cited by 4
Self-citationXu, Q., Yang, J., Cheng, F., Ning, Z., Xi, C., & Sun, Z. (2023) · Brain Sciences · doi:10.3390/brainsci13121624 · Cited by 2
Niemeyer, C. S., Traina‐Dorge, V., Doyle‐Meyers, L. A., Das, A., Looper, J., Mescher, T., Feia, B., Medina, E. M., Nagel, M. A., Mahalingam, R., et al. (2024) · Journal of NeuroVirology · doi:10.1007/s13365-024-01196-w · Cited by 2
Walia, A., Shew, M. A., Durakovic, N., Herzog, J. A., Cirrito, J. R., Yuede, C. M., Wick, C. C., Manis, M., Holtzman, D. M., Buchman, C. A., et al. (2024) · Otolaryngology · doi:10.1002/ohn.942 · Cited by 2
Self-citationBiomarkers for Neurodegenerative Diseases
Abdelmoaty, M. M., Lu, E., & Foster, E. G. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_44 · Cited by 2
Nemati, R., Sohrabi-Ashlaghi, A., Saberian, P., Sadeghi, M., Mardani, S., Abadi, A., Yaghoobpoor, A., Heydari, A., Khoshroo, N., Rahnama, Y., et al. (2025) · BMC Neurology · doi:10.1186/s12883-025-04140-5 · Cited by 6
The biological diagnosis of Alzheimer’s disease using blood-based biomarkers: A Canadian prospective
Kumar, P., Mousavi, A., & Frykman, H. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.110980 · Cited by 2
Wilckens, K. A., & Chahine, L. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105075 · Cited by 2
One step towards dementia prevention
Frisoni, G. B., & Jessen, F. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30086-3 · Cited by 2
Diagnose It Yourself: Will There Be a Home Test Kit for Alzheimer’s disease?
Menne, F., & Schipke, C. G. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2020-0065 · Cited by 3
Fluid biomarkers for Alzheimer's disease in Down syndrome: Current status and novel trends
Iulita, M. F., Granholm, A., Carmona‐Iragui, M., Hamlett, E. D., Fortea, J., & Ledreux, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818845-3.00010-4 · Cited by 2
Plasma Biomarker for Alzheimer's Disease: Are We Ready Now for Clinical Practice and Drug Trials?
Nakamura, A. (2018) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.24 · Cited by 2
Current and Developing Methods for Diagnosing Alzheimer's Disease
Fuller, S. J., Carrigan, N., Sohrabi, H. R., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch3 · Cited by 2
Pronko, P. S., Zimatkin, S. M., & Kuz'mich, A. B. (1994) · PubMed · Cited by 2
Blood plasma biomarkers for Alzheimer’s disease: Aβ1–42/1–40 vs. AβX–42/X–40
Klafki, H., Wirths, O., Jahn, O., Morgado, B., Esselmann, H., & Wiltfang, J. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-0990 · Cited by 2
Aβ Imaging in Aging, Alzheimer’s Disease, and Other Neurodegenerative Conditions
Villemagne, V. L., Doré, V., Burnham, S. C., & Rowe, C. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_10 · Cited by 2
Optimized Pre-analytical Handling Protocol for Blood-Based Biomarkers of Alzheimer’s Disease
Jethwa, A., & Stöckl, L. (2024) · Methods in molecular biology · doi:10.1007/978-1-0716-3774-6_5 · Cited by 1
Major or Mild Vascular Neurocognitive Disorder
Espiritu, A. I., Balakrishnar, K., Moradizadeh, M., Marlatt, N. E., & Burhan, A. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-47802-4_21 · Cited by 1
Biomarkers for Alzheimer's Disease
Panwar, D., Sharma, P., Sharma, S., Malik, M., & Kaur, J. (2024) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/979-8-3693-6442-0.ch003 · Cited by 1
Elmaaty, A. A. A., Eissa, M. A., El-Rashedy, S. K., Zehry, H. I., Mosa, A. A. H., Zarad, C. A., Abdel-Dayem, M. A., Nokrashy, A. E., & Elsherifi, S. S. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00912-x · Cited by 1
Prognostic Value of A/T/N Biomarkers
Yim, S., Gu, Y., Kang, H., Shin, D., Jang, H., Yoo, H., Zetterberg, H., Blennow, K., González‐Ortiz, F., Ashton, N. J., et al. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006088 · Cited by 1
Hernández, S., Valladares‐Rodríguez, S., Novo, M., & Al‐Soufi, W. (2025) · Journal of dementia and Alzheimer's disease · doi:10.3390/jdad2040038 · Cited by 1
Dybing, K. M., Gao, S., Saykin, A. J., Risacher, S. L., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251401201 · Cited by 1
Delaby, C., & Lehmann, S. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1731 · Cited by 1
Zamani, J., Vahid, A., Wilson, E. N., Hosseini, S. M. H., & Initiative, T. F. L. D. N. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71265 · Cited by 1
Nasim, A., Fairman, D., Nixon, E., Jagdale, P., Cui, Z., Mohan, K., & Yates, J. W. T. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70255 · Cited by 1
Asiri, Z. A., Rhouati, A., Cialla‐May, D., Popp, J., & Zourob, M. M. (2026) · Microchemical Journal · doi:10.1016/j.microc.2026.118203 · Cited by 1
Applications of Top‐Down Protein Analysis in Clinical Diagnostics
Mann, M. W., Yeung, P. S.-W., & Luo, Y. R. (2026) · Mass Spectrometry Reviews · doi:10.1002/mas.70030 · Cited by 1
Diamond, A. B., Fried, P. J., Buss, S. S., Mullington, J. M., Brown, J. C., MacDonnell, K., & Mattos, M. K. (2026) · International Review of Psychiatry · doi:10.1080/09540261.2026.2671089 · Cited by 1
Plasma Amyloid Beta and Tau Associations with Cerebral Amyloid Angiopathy Presence and Severity
Bax, F., Liu, L., van Harten, T. W., Gökçal, E., Horn, M. J., Warren, A., Saba, A., Shirzadi, Z., DiPucchio, Z. Y., Schwab, K. M., et al. (2026) · Annals of Neurology · doi:10.1002/ana.78264 · Cited by 1
Kurz, C., Hattenkofer, D., Pihale-Haug, M., Hufnagel, A., Guersel, S., Brendel, M., Rauchmann, B., Levin, J., Höglinger, G. U., & Perneczky, R. (2026) · Aging Clinical and Experimental Research · doi:10.1007/s40520-026-03420-5 · Cited by 2
Delaby, C., & Lehmann, S. (2026) · Laboratory Service · doi:10.17116/labs20261502137 · Cited by 1
From Brain to Blood: Point-of-Care Detection of Biomarkers in Neurological Diseases
Han, S., Feng, E. J., & Xiong, L. (2026) · ACS Sensors · doi:10.1021/acssensors.6c01472 · Cited by 1
A Novel Therapy for Huntington's Disease.
Ar, L. S. (2018) · Europe PMC (PubMed Central) · Cited by 1
Ataka, T., Kimura, N., Kaneko, N., Masuda, T., Takeuchi, Y., Yabuuchi, K., Mizukami, T., Takeuchi, T., Ito, T., Tasai, H., et al. (2024) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70008 · Cited by 1
Biomarkers used in Alzheimer's disease diagnosis
Mishra, S. K., Singh, R., Chang, H., Obaid, A. A., & Singh, S. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15540-6.00013-6 · Cited by 1
Neuropathology meets chemical and genetic pathology head-on: a personal perspective
Masters, C. L. (2024) · Pathology · doi:10.1016/j.pathol.2024.11.001 · Cited by 1
Diagnostics and Therapeutics: The Yin and Yang of Diseases Such as Alzheimer
Ladenson, J. H. (2019) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2019.029603 · Cited by 1
Quantitative Mass Spectrometric Assay of Whole and CNBr-Cleaved Amyloid-β Peptides in Human Brain
Furman, R., Ng, S. C. W., Komatsu, H., & Axelsen, P. H. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190647 · Cited by 1
Emerging blood-based biomarkers for Alzheimer disease
Bekris, L. M., & Leverenz, J. B. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.87a.20133 · Cited by 1
Nho, K. T., Kueider‐Paisley, A., Arnold, M., MahmoudianDehkordi, S., Risacher, S. L., Louie, G., Blach, C., Baillie, R., Han, X., Kastenmueller, G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.25.394262 · Cited by 1
Adeola, H. A., & Robinson, R. A. S. (2025) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.5c00074 · Cited by 1
In the Pipeline-Alzheimer's Disease
Hurley, D. (2017) · Neurology Today · doi:10.1097/01.nt.0000527321.66606.f8
In the Pipeline-Alzheimer's Disease
FitzGerald, S. F. (2018) · Neurology Today · doi:10.1097/01.nt.0000531198.45994.44
Discovering Biomarkers of Alzheimer's Disease by Statistical Learning Approaches
Long, J. (2019) · PEARL (University of Plymouth) · doi:10.24382/645
The postsynaptic protein neurogranin: a new item in the Alzheimer’s disease biomarker toolbox
Kvartsberg, H. (2019) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Blood Tests for Alzheimer's Disease and Related Disorders
Reiman, E. M. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.20
Hurley, D. (2019) · Neurology Today · doi:10.1097/01.nt.0000579948.44540.5d
Biomarcadores en la demencia tipo alzheimer: sistema sanitario y edadismo
Balea-Fernandez, F., & Ramírez, J. A. (2020) · International Journal of Developmental and Educational Psychology Revista INFAD de psicología · doi:10.17060/ijodaep.2020.n1.v1.1781
A Simpler and Sensitive Mass Spectrometry Method for Quantitation of Plasma Amyloid Peptides?
Carson, J. P. (2021) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfab019
Anti-aging Medical Check-up and Evidence of Its Benefits
Yonei, Y., Yagi, M., & Meno, M. (2021) · doi:10.11320/ningendockitn.8.1_3
Conjunto de pruebas para los servicios de Google Maps
Baldó, S., & Antonio, D. (2015)
The Longitudinal Development of Corporate Environmental Strategy in the U.S.
Dahlmann, F., & Brammer, S. J. (2008)
Recent advances in blood and gut microbiota biomarkers for Alzheimer’s disease
Wu, S., Li, H., Tong, L., & Zhou, L. I. U. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0100
Metadata
- Authors
- Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., Benzinger, T., Fagan, A. M., Patterson, B. W., & Bateman, R. J.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Bateman, Randall J.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2017-07-19
- Volume
- 13
- Issue
- 8
- Pages
- 841-849
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC5567785
- OpenAlex
- W2736518852
- Cited by
- 585
- References
- 18
- Citations by year
- 2026: 44 · 2025: 44 · 2024: 74 · 2023: 65 · 2022: 84 · 2021: 85 · 2020: 70 · 2019: 66 · 2018: 47 · 2017: 2
- FWCI
- 37.40
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- MetLife Foundation
- AbbVie
- Amgen
- AstraZeneca
- Biogen
- Eisai
- Pfizer
- Sanofi
- Avid Radiopharmaceuticals
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- amyloid-beta, plasma amyloid-beta
- MeSH terms
- Aged, Amyloidosis, Chromatography, Liquid, Humans, Isotope Labeling, Kinetics, Peptide Fragments, Prospective Studies, ROC Curve, Mass Spectrometry, Biomarkers, Single-Blind Method, Amyloid beta-Peptides, Area Under Curve, Immunoprecipitation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
